Drugs / Norgestimate/ethinyl estradiol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00745901 | May → Oct 2008 | — | Ortho-McNeil Janssen Scientific Affairs, LLC | Completed | Mixed |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Norgestimate/ethinyl estradiol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00745901 ↗ |
| Known as | norgestimate/ethinyl E2 | “healthy, sexually active women were assigned randomly to a 21/7-day (norgestimate/ethinyl E2) or 24/4-day (drospirenone/ethinyl E2) OCP regimen.” PMID 19935020 ↗ Dec 2009 |
| Route | Oral | “a 21/7-day triphasic norgestimate/ethinyl estradiol (E2) 25-microgram oral contraceptive pill (OCP) and a 24/4-day drospirenone/ethinyl E2 20-microgram OCP.” PMID 19935020 ↗ Dec 2009 |